Article summary
The European Medicines Agency (EMA) has begun to evaluate an application for Spikevax, the coronavirus (COVID-19) vaccine made by Moderna, to be given as a booster jab to people six months after being fully vaccinated. The scope of Moderna’s application is for its Spikevax vaccine to be given as a booster to all fully vaccinated people aged 12 and above so that it improves protection after it has waned. The application follows the EMA and European Centre for Disease Prevention and Control's (ECDC) previous statement that booster jabs should be considered for people with weakened immune systems.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial